Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care.
Munson Healthcare’s Cowell Family Cancer Center won a 2024 ACCC Innovator Award for its bispecific T-cell engager therapy program, which offers a viable alternative to CAR T-cell therapy for patients with relapsed and refractory cancers. Learn how this pharmacist-led program manages unique toxicities with meticulous planning and patient education in this month’s Oncology Issues.
ACCCBuzz spotlights Munson Healthcare, Cowell Family Cancer Center in Traverse City, MI, one of the recipients of the 2024 ACCC Innovator Award.